Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The study will address the impact of genetical variation of a protein involved in the
intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.